Cost-effectiveness analysis of ainuovirine versus efavirenz in HIV population initiating first-line combination antiretroviral therapy

被引：0
|
作者：
Yang, Chenlu [1 ]
Mi, Yuanqi [2 ]
Zeng, Yuhong [3 ]
Cheng, Feng [4 ]
Zheng, Yufang [5 ]
Zhang, Chunyun [5 ]
Qin, Hong [5 ]
Zeng, Huatang [6 ]
Zhou, Mengge
机构：
[1] Chinese Acad Med Sci, Dept Epidemiol & Biostat, Inst Basic Med Sci, Beijing, Peoples R China
[2] Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China
[3] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[4] Third Mil Med Univ, Dept Epidemiol, Coll Prevent Med, Army Med Univ, Chongqing, Peoples R China
[5] Jiangsu Aidea Pharmaceut Co Ltd, Clin Res & Dev, Yangzhou, Jiangsu, Peoples R China
[6] Shenzhen Hlth Dev Res & Data Management Ctr, Shenzhen, Peoples R China
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P267
引用
收藏
页码：237 / 237
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EFAVIRENZ VERSUS RILPIVIRINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
    Bonafede, M.
    Juday, T.
    Lenhart, G.
    Pan, K.
    Hebden, T.
    Correll, T.
    VALUE IN HEALTH, 2012, 15 (04) : A241 - A241
  • [2] Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda
    Sempa, Joseph
    Ssennono, Mark
    Kuznik, Andreas
    Lamorde, Mohammed
    Sowinski, Stefanie
    Semeere, Aggrey
    Hermans, Sabine
    Castelnuovo, Barbara
    Manabe, Yukari C.
    BMC PUBLIC HEALTH, 2012, 12
  • [3] Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda
    Joseph Sempa
    Mark Ssennono
    Andreas Kuznik
    Mohammed Lamorde
    Stefanie Sowinski
    Aggrey Semeere
    Sabine Hermans
    Barbara Castelnuovo
    Yukari C Manabe
    BMC Public Health, 12
  • [4] COST-EFFECTIVENESS OF EFAVIRENZ COMPARED WITH GENERIC NEVIRAPINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
    Bonafede, M. M.
    Juday, T.
    Farr, A.
    Lenhart, G. M.
    Hebden, T.
    Correll, T.
    VALUE IN HEALTH, 2013, 16 (03) : A92 - A92
  • [5] Cost-Effectiveness of Tenofovir as First-Line Antiretroviral Therapy in India
    Bender, Melissa A.
    Kumarasamy, Nagalingeswaran
    Mayer, Kenneth H.
    Wang, Bingxia
    Walensky, Rochelle P.
    Flanigan, Timothy
    Schackman, Bruce R.
    Scott, Callie A.
    Lu, Zhigang
    Freedberg, Kenneth A.
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (03) : 416 - 425
  • [6] COST-EFFECTIVENESS OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR COMPARED WITH EFAVIRENZ/EMTRICITABINE/TENOFOVIR AS FIRST-LINE HIV ANTIRETROVIRAL THERAPY IN THE ADULT POPULATION IN THE UNITED STATES
    Juday, T.
    Correll, T.
    Bentley, T.
    Broder, M.
    VALUE IN HEALTH, 2013, 16 (03) : A92 - A93
  • [7] Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection
    Simpson, KN
    Luo, MP
    Chumney, E
    Sun, E
    Brun, S
    Ashraf, T
    HIV CLINICAL TRIALS, 2004, 5 (05): : 294 - 304
  • [8] Cost-effectiveness analysis of first-line HAART
    Maggiolo, F.
    Di Matteo, S.
    Masini, G.
    Astuti, N.
    Di Filippo, E.
    Bernardini, C.
    Soavi, L.
    Colombo, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 69 - 70
  • [9] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345